THN102
Experimental alertness-boosting drug combination (modafinil and flecainide) that is not yet proven in humans.

Pharmacology
Contents
DETAILED OVERVIEW
What is THN102?
THN102 is an experimental drug combination that pairs the well-known wakefulness-promoting drug modafinil with flecainide, a medicine for heart rhythm disorders. It is not approved for any use and is still in clinical development. It has been studied in sleep deprivation and in the excessive daytime sleepiness that comes with Parkinson's disease.
In the brain, flecainide blocks the connections between astrocytes, the cells that support nerve cells, and this amplifies the effect of modafinil. In animal studies and early human studies, the combination showed better alertness than modafinil alone and also improved working memory, but the human data are still limited and the effect is not proven in people. Headache, insomnia, nausea and dry mouth may occur. Flecainide can also trigger heart rhythm problems, so the combination is contraindicated in heart disease, serious rhythm disorders and after a previous severe skin reaction. There are no safety data for pregnancy and breastfeeding. Because of the modafinil, it counts as prohibited in competitive sport.
Mechanism
Modafinil (DAT) + glial connexin inhibition (flecainide)
Half-life
Modafinil ~12-15 h; low-dose flecainide ~12-27 h
Onset
~30-60 min (modafinil component)
Legal status
Investigational, not approved (Phase 2)
Developer
Theranexus
THN102 is known mainly in a clinical-development context rather than as a widespread community supplement, so first-hand recreational reports are scarce. The distinctive idea researchers highlight is the neuron-glia approach: pairing modafinil with a sub-therapeutic dose of flecainide to engage astrocyte connexins and squeeze more vigilance and cognitive benefit out of a given modafinil dose. Trial reports describe a wakefulness and working-memory signal that can exceed plain modafinil, with a tolerability profile similar to modafinil at the low flecainide doses tested. Because one component is an antiarrhythmic, cardiac caution and medical supervision are emphasized, and the compound remains investigational rather than an established agent.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- Dopamine transporter (DAT), modafinil componentModerate
- Astroglial connexins Cx30/Cx43 (gap junctions), low-dose flecainideModerate
- Arousal circuit (cortex, striatum, amygdala)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Headache (modafinil-type, common)
- Insomnia, sleep disturbance (especially when dosed late in the day)
- Nausea, dry mouth, decreased appetite (modafinil-type)
- Anxiety, nervousness, irritability
- Cardiac effect: flecainide is an antiarrhythmic, proarrhythmic at higher doses (the low dose used in trials was well tolerated)
- Limited human safety data: investigational combination, full side-effect spectrum unknown
Contraindications · 5
- Structural or ischemic heart disease, serious arrhythmia (because of the class Ic antiarrhythmic flecainide component)
- History of serious skin reaction (SJS, TEN, DRESS) or modafinil hypersensitivity
- Pregnancy and breastfeeding: no clinical safety data, avoid
- Drug interactions: modafinil CYP3A4 induction (contraceptives), flecainide CYP2D6 metabolism (CYP2D6 inhibitors raise its levels)
- Not an approved drug, investigational combination; not recommended for unsupervised self-treatment
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target
Sauvet F, Erblang M, Gomez-Merino D, et al.
THN102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial
Corvol JC, Azulay JP, Bosse B, et al.
Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination
Vodovar D, Duchene A, Wimberley C, et al.
Impact of Astroglial Connexins on Modafinil Pharmacological Properties
Duchene A, Perier M, Zhao Y, et al.
FAQ
FAQ
THN102 is an experimental drug pairing the well-known wakefulness booster modafinil with a very low dose of a heart-rhythm medication (flecainide), aiming to sharpen alertness and focus even more than modafinil alone, especially under sleep deprivation. Human trials showed better vigilance than modafinil by itself and improved working memory, but this is still early-stage research, not an established, ready-to-use drug.
Telegram
Have a question about THN102?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.